“点击蓝字 关注我们恒瑞创新药注射用磷罗拉匹坦帕洛诺司琼新适应证上市许可申请获受理PPS近日,恒瑞医药子公司福建盛迪医药有限公司收到国家药品监督管理局下发的《受理通知书》,公司自主研发的1类创新药注射用磷罗拉匹坦帕洛诺司琼(瑞坦宁®)新适应证上市许可申请获国家药监局受理,适应证为:用于成年患者预防中度致吐性抗肿瘤药物引起的急性和迟发性恶心和呕吐。关于HR20013-302研究此次申报新适应证,是...
Source Link“点击蓝字 关注我们恒瑞创新药注射用磷罗拉匹坦帕洛诺司琼新适应证上市许可申请获受理PPS近日,恒瑞医药子公司福建盛迪医药有限公司收到国家药品监督管理局下发的《受理通知书》,公司自主研发的1类创新药注射用磷罗拉匹坦帕洛诺司琼(瑞坦宁®)新适应证上市许可申请获国家药监局受理,适应证为:用于成年患者预防中度致吐性抗肿瘤药物引起的急性和迟发性恶心和呕吐。关于HR20013-302研究此次申报新适应证,是...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.